[1]王青丽,李 喆,刘 扬,等.曲克芦丁脑蛋白水解物治疗脑梗死的疗效和安全性Meta分析[J].医学信息,2023,36(14):52-59.[doi:10.3969/j.issn.1006-1959.2023.14.010]
　WANG Qing-li,LI Zhe,LIU Yang,et al.Meta-analysis of the Efficacy and Safety of Troxerutin and Cerebroprotein Hydrolysate Injection in the Treatment of Cerebral Infarction[J].Journal of Medical Information,2023,36(14):52-59.[doi:10.3969/j.issn.1006-1959.2023.14.010]
点击复制

曲克芦丁脑蛋白水解物治疗脑梗死的疗效和安全性Meta分析()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
36卷
期数:
2023年14期
页码:
52-59
栏目:
医学数据科学
出版日期:
2023-07-15

文章信息/Info

Title:
Meta-analysis of the Efficacy and Safety of Troxerutin and Cerebroprotein Hydrolysate Injection in the Treatment of Cerebral Infarction
文章编号:
1006-1959（2023）14-0052-08
作者:
王青丽; 李 喆; 刘 扬; 等
（郑州大学第二附属医院脑血管病科/河南省脑血管病转化医学重点实验室，河南 郑州 450000）
Author(s):
WANG Qing-li; LI Zhe; LIU Yang; et al.
(Department of Cerebrovascular Diseases,the Second Affiliated Hospital of Zhengzhou University/Henan Medical Key Laboratory of Translational Cerebrovascular Diseases,Zhengzhou 450000,Henan,China)
关键词:
曲克芦丁脑蛋白水解物; 脑梗死; 缺血性脑卒中; 随机对照试验
Keywords:
Troxerutin and cerebroprotein hydrolysate injection; Cerebral infarction; Ischemic stroke; Randomized controlled trial
分类号:
R743.3
DOI:
10.3969/j.issn.1006-1959.2023.14.010
文献标志码:
A
摘要:
目的 系统评价曲克芦丁脑蛋白水解物治疗脑梗死的疗效和安全性。方法 计算机检索中国生物医学文献数据库（CBM）、中国期刊全文数据库（CNKI）、万方数据库（Wangfang Data）、维普数据库（VIP）、PubMed、Cochrane Library、EMbase、Web of Science数据库，检索时限为建库至2022年6月。根据纳入和排除标准筛选曲克芦丁脑蛋白水解物治疗脑梗死的临床随机对照试验（RCTs），对纳入的研究进行资料提取和系统评价后，采用RevMan5.4软件进行Meta分析。结果 纳入16项研究，共1681例患者，其中治疗组963例，对照组718例。治疗组有效率高于对照组，差异有统计学意义[RR=1.26，95%CI（1.19，1.33），Z=8.26，P＜0.05]；治疗组神经功能缺损改善程度高于对照组，差异有统计学意义[MD=-3.56，95%CI（-4.14，-2.98），Z=12.07，P＜0.05]；治疗组日常生活活动能力提高程度优于对照组，差异有统计学意义[MD=13.32，95%CI（11.66，14.98），Z=15.75，P＜0.05]；治疗组不良反应发生率高于对照组，但差异无统计学意义[RR=0.66,95%CI（0.40，1.09），Z=1.64，P=0.10]；治疗组全血低切黏度变化幅度高于对照组，差异有统计学意义[高切黏度：MD=-1.16，95%CI（-2.42，0.10），Z=1.8，P=0.07；低切黏度：MD=-2.19，95%CI（-2.94，-1.43），Z=5.70，P＜0.05]；治疗组血浆纤维蛋白原降低幅度高于对照组，差异有统计学意义[MD=-0.44，95%CI（-0.49，-0.40），Z=19.13，P＜0.05]。结论 曲克芦丁脑蛋白水解物治疗脑梗死疗效确切，可有效改善神经功能缺损程度，提升日常生活活动能力，且安全性好。
Abstract:
Objective To systematically review the efficacy and safety of troxerutin and cerebroprotein hydrolysate injection in the treatment of cerebral infarction.Methods Chinese BioMedical Literature Database (CBM), Chinese Journal Full-text Database (CNKI), Wanfang Database (Wangfang Data), VIP Database (VIP), PubMed, Cochrane Library, Embase, Web of Science database were searched by computer. The retrieval time limit was from the establishment of the database to June 2022. According to the inclusion and exclusion criteria, the clinical randomized controlled trials (RCTs) of troxerutin cerebroprotein hydrolysate in the treatment of cerebral infarction were screened. After data extraction and systematic evaluation of the included studies, RevMan5.4 software was used for Meta analysis.Results A total of 16 studies involving 1681 cases were included, while 963 cases in the treatment group and 718 cases in the control group. The effective rate of the treatment group was higher than that of the control group, and the difference was statistically significant [RR=1.26, 95%CI(1.19, 1.33), Z=8.26, P<0.05]. The improvement of neurological deficits in the treatment group was higher than that in the control group, and the difference was statistically significant [MD=-3.56,95%CI(-4.14, -2.98), Z=12.07, P<0.05]. The improvement of activities of daily living in the treatment group was better than that in the control group, and the difference was statistically significant [MD=13.32, 95%CI(11.66, 14.98), Z=15.75, P<0.05]. The incidence of adverse reactions in the treatment group was higher than that in the control group, but the difference was not statistically significant [RR=0.66, 95%CI(0.40, 1.09), Z=1.64, P=0.10]. The change range of whole blood low shear viscosity in the treatment group was higher than that in the control group, and the difference was statistically significant [high shear viscosity: MD=-1.16, 95%CI(-2.42, 0.10), Z=1.8, P=0.07; low shear viscosity: MD=-2.19, 95%CI(-2.94, -1.43), Z=5.70, P<0.05]. The decrease of fibrinogen in the treatment group was higher than that in the control group, and the difference was statistically significant [MD=-0.44, 95%CI(-0.49, -0.40), Z=19.13, P<0.05].Conclusion Troxerutin cerebroprotein hydrolysate is effective in the treatment of cerebral infarction, which can effectively improve the degree of neurological deficit, improve the ability of daily living activities, and has good safety.

参考文献/References:

[1]Takeda H,Yamaguchi T,Yano H,et al.Microglial metabolic disturbances and neuroinflammation in cerebral infarction[J].J Pharmacol Sci,2021,145(1):130-139.[2]Huang P,He XY,Xu M.Effect of Argatroban Injection on Clinical Efficacy in Patients with Acute Cerebral Infarction: Preliminary Findings[J].Eur Neurol,2021,84(1):38-42.[3]Zhao Y,Zhang X,Chen X,et al.Neuronal injuries in cerebral infarction and ischemic stroke: From mechanisms to treatment (Review)[J].Int J Mol Med,2022,49(2):15. [4]Sui R,Zang L,Bai Y.Administration of troxerutin and cerebroprotein hydrolysate injection alleviates cerebral ischemia/reperfusion injury by down-regulating caspasemolecules[J].Neuropsychiatr Dis Treat,2019,15:2345-2352.[5]Zhào H,Wang R,Zhang Y,et al.Neuroprotective effects of troxerutin and cerebroprotein hydrolysate injection on the neurovascular unit in a rat model of Middle cerebral artery occlusion[J].Int J Neurosci,2021,131(3):264-278.[6]Zhào H,Liu Y,Zeng J,et al.Troxerutin and Cerebroprotein Hydrolysate Injection Protects Neurovascular Units from Oxygen-Glucose Deprivation and Reoxygenation-Induced Injury In Vitro[J].Evid Based Complement Alternat Med,2018,2018:9859672.[7]Ma W,Wang S,Liu X,et al.Protective effect of troxerutin and cerebroprotein hydrolysate injection on cerebral ischemia through inhibition of oxidative stress and promotion of angiogenesis in rats[J].Mol Med Rep,2019,19(4):3148-3158.[8]中华医学会神经病学分会,中华医学会神经病学分会脑血管病学组.中国急性缺血性脑卒中诊治指南2014[J].中华神经科杂志,2015,48(4):246-257.[9]各类脑血管疾病诊断要点[J].中华神经科杂志,1996(6):60-61.[10]脑卒中患者临床神经功能缺损程度评分标准(1995)[J].中华神经科杂志,1996(6):62-64.[11]丁度宇.长春西汀注射液联合脑蛋白水解物治疗脑梗死的效果[J].深圳中西医结合杂志,2020,30(1):180-182.[12]于红梅.氯吡格雷联合曲克芦丁脑蛋白水解物对脑梗死患者影响[J].中国处方药,2021,19(8):82-83.[13]信廷想.长春西汀联合曲克芦丁脑蛋白水解物对急性脑梗死的疗效观察[J].河南医学研究,2018,27(24):4545-4546.[14]冯晴,余晓峰,王大鹏,等.曲克芦丁脑蛋白水解物联合依达拉奉治疗急性脑梗死疗效分析[J].深圳中西医结合杂志,2020,30(24):145-146.[15]刘景隆.曲克芦丁脑蛋白水解物注射液治疗急性脑梗死疗效观察[J].青海医药杂志,2013,43(7):16-17.[16]吴静.曲克芦丁脑蛋白水解物治疗急性脑梗死的临床疗效及对神经功能的影响[J].医学理论与实践,2018,31(16):2380-2381,2393.[17]常红云,丁彦.曲克芦丁脑蛋白水解物联合舒血宁对急性脑梗死患者神经功能及血液高凝状态的影响[J].中国药业,2018,27(23):47-49.[18]张俊波,张深山,黄国武.依达拉奉与曲克芦丁脑蛋白水解物治疗急性脑梗死患者的效果分析[J].实用中西医结合临床,2021,21(12):98-99.[19]张宏祥.急性缺血性脑卒中患者应用依达拉奉联合曲克芦丁脑蛋白水解物的疗效及安全性观察[J].药品评价,2019,16(20):41-42.[20]朱锦莉.尤瑞克林联合曲克芦丁脑蛋白水解物对急性脑梗死患者凝血功能及神经功能的影响[J].实用临床医药杂志,2016,20(9):17-20.[21]杨长路,荆艳.尤瑞克林联合曲克芦丁脑蛋白水解物对急性脑梗死患者凝血功能及神经功能的影响[J].医学信息,2020,33(18):150-151.[22]董卫华.曲克芦丁脑蛋白水解物注射液治疗恢复期脑梗死的临床观察[J].医学信息,2015,28(13):172.[23]董文韬,区健刚,刘彩月,等.丹红联合曲克芦丁脑蛋白水解物治疗急性脑梗死疗效分析[J].广州医药,2021,52(3):32-35.[24]邹东勇,蒋波.曲克芦丁脑蛋白水解物注射液辅助治疗急性脑梗死的效果及对患者神经功能和脑血流动力学的影响[J].临床合理用药杂志,2020,13(35):6-8.[25]陈海波,梁克山,周绍新,等.曲克芦丁脑蛋白水解物注射液治疗急性脑梗死的随机、单盲和安慰剂对照研究[J].中国神经免疫学和神经病学杂志,2016,23(4):251-255.[26]颜世鹏,王春阳.普洛迪治疗缺血性脑卒中157例临床观察[J].实用心脑肺血管病杂志,2006,14(10):790.[27]Wen H,Lv M.Correlation analysis between serum procalcitonin and infarct volume in young patients with acute cerebral infarction[J].Neurological Sciences,2021,42(8):3189-3196.[28]Li X,Bu S,Pan RR,et al.The values of AHCY and CBS promoter methylation on the diagnosis of cerebral infarction in Chinese Han population[J].BMC Medical Genomics,2020,13(1):163.[29]Zamanian M,Bazmandegan G,Sureda A,et al.The Protective roles and molecular mechanisms of troxerutin (Vitamin P4) for the treatment of chronic diseases: A Mechanistic Review[J].Curr Neuropharmacol,2021,19(1):97-110.[30]宋江峰.依达拉奉联合曲克芦丁脑蛋白水解物对急性缺血性脑卒中患者的疗效[J].西藏医药,2022,43(5):62-64.[31]Ren Y,Ma X,Wang T,et al.The cerebroprotein Hydrolysate-I plays a neuroprotective effect on cerebral ischemic stroke by inhibiting MEK/ERK1/2 signaling pathway in rats[J].Neuropsychiatr Dis Treat,2021,17:2199-2208.[32]Cao W,Zhang C,Chen R,et al.A novel cerebroprotein hydrolysate,CH1,ameliorates chronic focal cerebral ischemia injury by promoting white matter integrity via the Shh/Ptch-1/Gli-1 signaling pathway[J].Neuropsychiatr Dis Treat,2020,16:3209-3224.[33]An L,Han X,Li H,et al.Effects and mechanism of cerebroprotein hydrolysate on learning and memory ability in mice[J].Genet Mol Res,2016,15(3):27525868.

相似文献/References:

[1]刘海威.延续性护理对脑梗死运动功能障碍患者生活质量及社会支持的影响[J].医学信息,2018,31(02):160.[doi:10.3969/j.issn.1006-1959.2018.02.062]
　LIU Hai-wei.Effect of Continuous Nursing on Quality of Life and Social Support in Patients with Motor Dysfunction of Cerebral Infarction[J].Journal of Medical Information,2018,31(14):160.[doi:10.3969/j.issn.1006-1959.2018.02.062]
[2]韩艳庆,董 成,徐 玲.脑梗死并发急腹症诊治分析[J].医学信息,2018,31(06):188.[doi:10.3969/j.issn.1006-1959.2018.06.068]
　HAN Yan-qing,DONG Cheng,XU Ling.Analysis of Diagnosis and Treatment of Acute Cerebral Infarction Complicating Acute Abdominal Disease[J].Journal of Medical Information,2018,31(14):188.[doi:10.3969/j.issn.1006-1959.2018.06.068]
[3]王明远,陈海燕,张延朋,等.颈动脉斑块、血同型半胱氨酸及血尿酸对短暂性脑缺血 发作进程的影响研究[J].医学信息,2018,31(08):65.[doi:10.3969/j.issn.1006-1959.2018.08.020]
　WANG Ming-yuan,CHEN Hai-yan,ZHANG Yan-peng,et al.Effects of Carotid Plaque,Homocysteine and Serum Uric Acid on Transient Ischemic Attack[J].Journal of Medical Information,2018,31(14):65.[doi:10.3969/j.issn.1006-1959.2018.08.020]
[4]甘雪梅.系统护理对脑梗死患者生活质量及满意度的影响[J].医学信息,2018,31(08):172.[doi:10.3969/j.issn.1006-1959.2018.08.062]
　GAN Xue-mei.Effect of Systematic Nursing on Quality of Life and Satisfaction of Patients with Cerebral Infarction[J].Journal of Medical Information,2018,31(14):172.[doi:10.3969/j.issn.1006-1959.2018.08.062]
[5]单 敏,常燕燕,赵大鹏,等.急性前循环脑梗死患者梗死体积与 血清NSE水平相关性研究[J].医学信息,2018,31(10):1.[doi:10.3969/j.issn.1006-1959.2018.10.001]
　SHAN Min,CHANG Yan-yan,ZHAO Da-peng,et al.Correlation between Infarct Volume and Serum NSE Level in Patients with Acute Anterior Circulation Cerebral Infarction[J].Journal of Medical Information,2018,31(14):1.[doi:10.3969/j.issn.1006-1959.2018.10.001]
[6]陈艳男,徐 劲.脑梗死患者血清SAA、hs-CRP与颅内动脉粥样硬化狭窄程度的相关性[J].医学信息,2022,35(09):120.[doi:10.3969/j.issn.1006-1959.2022.09.030]
　CHEN Yan-nan,XU Jin.Correlation Between Serum SAA, hs-CRP and Intracranial Atherosclerotic Stenosis in Patients with Cerebral Infarction[J].Journal of Medical Information,2022,35(14):120.[doi:10.3969/j.issn.1006-1959.2022.09.030]
[7]李福滔,张素平.单侧颈内动脉夹层致脑梗死1例报道[J].医学信息,2018,31(11):191.[doi:10.3969/j.issn.1006-1959.2018.11.065]
[8]张怀祥,段晓宇.脑梗死后认知障碍的病理学机制、相关危险因素及治疗[J].医学信息,2018,31(16):21.[doi:10.3969/j.issn.1006-1959.2018.16.007]
　ZHANG Huai-xiang,DUAN Xiao-yu.Pathological Mechanism,Related Risk Factors and Treatment of Cognitive Impairment after Cerebral Infarction[J].Journal of Medical Information,2018,31(14):21.[doi:10.3969/j.issn.1006-1959.2018.16.007]
[9]柳 星,卢会琴.脑梗死恢复期的临床路径实施效果分析[J].医学信息,2018,31(19):128.[doi:10.3969/j.issn.1006-1959.2018.19.038]
　LIU Xing,LU Hui-qin.Analysis of Clinical Path Implementation in the Recovery Period of Cerebral Infarction[J].Journal of Medical Information,2018,31(14):128.[doi:10.3969/j.issn.1006-1959.2018.19.038]
[10]吴永惠.缺血性中风病的中医药治疗[J].医学信息,2022,35(12):89.[doi:10.3969/j.issn.1006-1959.2022.12.021]
　WU Yong-hui.Traditional Chinese Medicine Treatment of Ischemic Stroke[J].Journal of Medical Information,2022,35(14):89.[doi:10.3969/j.issn.1006-1959.2022.12.021]

更新日期/Last Update: 1900-01-01